YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

Generic Drug Debates

March 6, 2012 | A feature of Obama's health care plan was cheaper generic drug options, but that's proving easier said than done. Approving biosimilars is a complex and drawn-out process, and an "interchangable" classification is still under debate. FDA will hold a hearing on May 11 to review the label. The discount percentage is also unclear, with numbers ranging from 10% to 90% off branded products. Huffington Post
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.